Redhill Biopharma (RDHL) Stock Price, News & Analysis

Company Overview

RedHill Biopharma Ltd. was a specialty biopharmaceutical company focused on developing and commercializing therapies for gastrointestinal diseases and certain infectious diseases. The company was founded in Israel and conducted operations primarily in the United States, where it pursued regulatory approval, commercialization and clinical development activities.

RedHill’s principal commercial product was Talicia, an oral combination of rifabutin, amoxicillin and omeprazole approved by the U.S. Food and Drug Administration to treat Helicobacter pylori infection in adults. The company also commercialized Aemcolo, an oral, locally acting antibiotic formulation based on rifamycin for certain cases of travelers’ diarrhea. Its development pipeline included investigational treatments for gastrointestinal disorders, infections and other conditions, although not all of these programs reached approval.

RedHill was led for several years by Mark L. Sirgo, who served as president and chief executive officer. The company’s shares traded on the Nasdaq Capital Market under the symbol RDHL; however, RedHill subsequently faced significant operating and financial challenges, and its public-market listing and business activities were materially reduced. Information about its current operations and leadership may therefore be limited.

Key Stats

• Today's Range: $0.50 to $0.52
• 50-Day Range: $0.50 to $0.90
• 52-Week Range: $0.50 to $2.79
• Volume: 16,076 shs
• Average Volume: 847,263 shs
• Market Capitalization: $3.09 million
• P/E Ratio: 0.00
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Redhill Biopharma Stock Analysis - MarketRank™

Redhill Biopharma scored higher than 22% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Redhill Biopharma has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Redhill Biopharma has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Redhill Biopharma is 0.00, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.93.

Price to Earnings Ratio vs. Sector

The P/E ratio of Redhill Biopharma is 0.00, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 276.19.

Price to Book Value per Share Ratio

Redhill Biopharma has a P/B Ratio of 0.60. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.15% of the float of Redhill Biopharma has been sold short.

Short Interest Ratio / Days to Cover

Redhill Biopharma has a short interest ratio ("days to cover") of 0.31, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Redhill Biopharma has recently increased by 2,710.06%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Redhill Biopharma does not currently pay a dividend.

Dividend Growth

Redhill Biopharma does not have a long track record of dividend growth.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.39

News Sentiment

Redhill Biopharma has a news sentiment score of 0.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.74 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Redhill Biopharma this week, compared to 1 article on an average week.

Search Interest

4 people have searched for RDHL on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Redhill Biopharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

6.81% of the stock of Redhill Biopharma is held by insiders.

Percentage Held by Institutions

7.20% of the stock of Redhill Biopharma is held by institutions.

Company Calendar

• Last Earnings: 11/30/2021
• Today: 9/28/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:RDHL
• Previous Symbol: ASX:RDH
• CIK: 1553846
• Web: www.redhillbio.com
• Phone: 972-3541-3131
• Fax: 972-3541-3144
• Employees: 210
• Year Founded: 2009

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: 0.00
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.34
• Quick Ratio: 0.34

Sales & Book Value

• Annual Sales: $290 thousand
• Price / Sales: 10.67
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.83 per share
• Price / Book: 0.61

Miscellaneous

• Outstanding Shares: 6,080,000
• Free Float: 5,667,000
• Market Cap: $3.09 million
• Optionable: No Data
• Beta: 4.96